Early administration of magnesium sulfate and its impact on clinical outcomes in ICU-admitted patients with COPD: a retrospective cohort study
Authors:
Open Access
- 4 September 2025
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1616294
Abstract
Background: Magnesium sulfate is commonly utilized in critical care due to its vasodilatory, bronchodilatory, and neuroprotective properties. However, its impact on mortality outcomes in patients with chronic obstructive pulmonary disease (COPD) requiring intensive care remains inadequately defined.Methods: A retrospective cohort study was conducted on patients with COPD who were admitted to the ICU at Beth Israel Deaconess Medical Center in Boston from 2008 to 2019. Early administration of magnesium sulfate was considered for intravenous administration within 48 h of ICU admission. Propensity-score-based methods, such as inverse probability weighting, were employed to evaluate the correlation between early use of magnesium sulfate and 28-day mortality.Results: A total of 3,651 ICU admissions for COPD were included, of which 1,148 (31.4%) patients received magnesium sulfate within the first 48 h. Administering magnesium sulfate early was linked to a reduced 28-day mortality rate (hazard ratio 0.76, 95% confidence interval 0.60–0.95), with consistent results across predefined subgroups. This correlation remained consistent regardless of baseline serum magnesium levels and did not increase the risk of acute kidney injury (AKI). The calculated E-value of 1.96 indicates that significant unmeasured confounding factors would be necessary to fully account for the observed relationship.Conclusion: In this single-center retrospective cohort, early magnesium sulfate administration in critically ill patients with COPD was associated with lower 28-day mortality without an observed increase in AKI risk. These results advocate for prospective multicenter studies to validate these connections, investigate optimal dosing approaches, and pinpoint the patient subgroups most likely to benefit from this intervention.Keywords
This publication has 38 references indexed in Scilit:
- High serum magnesium level is associated with increased mortality in patients with sepsis: an international, multicenter retrospective studyMedcomm, 2024
- Association of magnesium sulfate use with mortality in critically ill patients with sepsis: a retrospective propensity score-matched cohort studyBritish Journal of Anaesthesia, 2023
- Magnesium sulfate for acute exacerbations of chronic obstructive pulmonary diseaseAnnals of Emergency Medicine, 2022
- Using the E-Value to Assess the Potential Effect of Unmeasured Confounding in Observational StudiesJAMA, 2019
- Inhaled magnesium sulfate in the treatment of acute asthmaCochrane Database of Systematic Reviews, 2017
- Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015The Lancet Respiratory Medicine, 2017
- Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015The Lancet, 2016
- Magnesium sulfate enhances non-depolarizing muscle relaxant vecuronium action at adult muscle-type nicotinic acetylcholine receptor in vitroActa Pharmacologica Sinica, 2011
- A Randomized Controlled Trial of Magnesium Sulfate, in Addition to Usual Care, for Rate Control in Atrial FibrillationAnnals of Emergency Medicine, 2005
- Magnesium Sulfate in Exacerbations of Chronic Obstructive Pulmonary DiseaseArchives of internal medicine (1960), 1995